- Home
- STEX vs ACHV Comparison
STEX vs ACHV Comparison
Compare STEX & ACHV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STEX
- ACHV
- Stock Information
- Founded
- STEX 2009
- ACHV N/A
- Country
- STEX United States
- ACHV United States
- Employees
- STEX N/A
- ACHV N/A
- Industry
- STEX
- ACHV Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- STEX
- ACHV Health Care
- Exchange
- STEX Nasdaq
- ACHV Nasdaq
- Market Cap
- STEX 172.1M
- ACHV 167.6M
- IPO Year
- STEX N/A
- ACHV N/A
- Fundamental
- Price
- STEX $3.70
- ACHV $4.38
- Analyst Decision
- STEX
- ACHV Strong Buy
- Analyst Count
- STEX 0
- ACHV 1
- Target Price
- STEX N/A
- ACHV $12.00
- AVG Volume (30 Days)
- STEX 821.4K
- ACHV 1.4M
- Earning Date
- STEX 11-14-2025
- ACHV 11-06-2025
- Dividend Yield
- STEX N/A
- ACHV N/A
- EPS Growth
- STEX N/A
- ACHV N/A
- EPS
- STEX N/A
- ACHV N/A
- Revenue
- STEX $13,000.00
- ACHV N/A
- Revenue This Year
- STEX N/A
- ACHV N/A
- Revenue Next Year
- STEX N/A
- ACHV N/A
- P/E Ratio
- STEX N/A
- ACHV N/A
- Revenue Growth
- STEX N/A
- ACHV N/A
- 52 Week Low
- STEX $0.40
- ACHV $1.84
- 52 Week High
- STEX $14.11
- ACHV $5.78
- Technical
- Relative Strength Index (RSI)
- STEX N/A
- ACHV 48.69
- Support Level
- STEX N/A
- ACHV $4.26
- Resistance Level
- STEX N/A
- ACHV $4.90
- Average True Range (ATR)
- STEX 0.00
- ACHV 0.34
- MACD
- STEX 0.00
- ACHV -0.12
- Stochastic Oscillator
- STEX 0.00
- ACHV 7.76
About STEX Streamex Corp. Common Stock
Streamex Corp is a Real World Asset (RWA) tokenization company with Institutional grade infrastructure to bring the gold and commodities market on chain. Enabled by a gold denominated treasury and tokenization technology powering the modern commodities market.
About ACHV Achieve Life Sciences Inc.
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for niceon.